DEXA Bone Density Interpretation by Decade of Life

What Do T-Score and Z-Score Actually Mean?

The T-score is the number most clinicians quote, and it compares your bone mineral density to the average peak density of a healthy 25-to-30-year-old of the same sex. One standard deviation on that scale translates to roughly a 10-to-12% difference in BMD and is associated with approximately a 1.5-to-2.5-fold increase in fracture risk per SD reduction, as confirmed in the Study of Osteoporotic Fractures cohort (N=9,516) [1]. The Z-score, by contrast, benchmarks you against people your own age. A Z-score below -2.0 in a premenopausal woman or a man under 50 signals that something beyond normal aging is depleting bone.

The WHO Classification System

The World Health Organization defined the four-category system now used globally [2]:

| Category | T-score | |---|---| | Normal | Above -1.0 | | Osteopenia (low bone mass) | -1.0 to -2.5 | | Osteoporosis | -2.5 or below | | Severe osteoporosis | -2.5 or below plus fragility fracture |

These thresholds were derived from white postmenopausal women in the original WHO technical report. Their direct application to men and non-white populations requires caution; the NOF/ASBMR recommend using the same T-score cutoffs for men but interpreting Z-scores with sex- and ethnicity-matched reference databases [3].

Why the Measurement Site Matters

The lumbar spine (L1-L4), femoral neck, and total hip are the three standard sites. Spine scores can be falsely elevated in older adults because degenerative arthritis and osteophytes add apparent density. The femoral neck T-score is the preferred single site for fracture-risk calculation and for applying WHO thresholds in adults over 60 [3].

Peak Bone Mass: The 20s and 30s Baseline

Peak bone mass is achieved between ages 25 and 30 in most people, accounting for approximately 60% of fracture risk later in life, according to data from the International Osteoporosis Foundation [4]. By definition, a healthy 25-year-old has a T-score of 0.0.

What an "Optimal" DEXA Looks Like at This Age

An optimal scan in the third decade shows a T-score at or above 0.0 at the femoral neck and lumbar spine. Any T-score below -1.0 before age 40 warrants a Z-score review and secondary-cause workup: celiac disease, hyperparathyroidism, low testosterone, and high-dose glucocorticoid use are the most frequent culprits.

Building Bone in the 20s and 30s

Resistance training, adequate calcium (1,000 mg per day from diet and supplement combined), and vitamin D sufficiency (serum 25-OH-D above 30 ng/mL) remain the cornerstones of bone accrual at this age [4]. No pharmacological agent is FDA-approved for bone building in premenopausal women with normal BMD.

Interpreting DEXA in the 40s

The 40s are a transition decade. Men sustain BMD reasonably well. Women, particularly in perimenopause, may begin losing 1-2% per year at the spine as estrogen declines. A T-score between -1.0 and -1.5 at this stage is not unusual and does not automatically require medication.

The Role of the Z-Score Here

A femoral neck Z-score below -2.0 in a 45-year-old woman is the more actionable number. The 2023 Endocrine Society clinical practice guideline on premenopausal osteoporosis states: "In premenopausal women, a Z-score of -2.0 or lower is defined as 'below the expected range for age' and is the preferred metric for identifying low BMD." [5]

Secondary Workup Panel

At this age, a low BMD result should trigger: serum calcium, phosphorus, alkaline phosphatase, 25-OH vitamin D, PTH, complete metabolic panel, CBC, TSH, and in women with irregular cycles, LH/FSH and estradiol. Testosterone and SHBG are added for men.

Interpreting DEXA in the 50s

The 50s, encompassing the average age of menopause (51.4 years in the United States per the Study of Women's Health Across the Nation) [6], bring the steepest rate of bone loss for women, often 2-3% per year at the spine in the first five years after the final menstrual period. Men lose bone at roughly 0.5-1% per year during this decade.

When to Start Screening

The U.S. Preventive Services Task Force (USPSTF) recommends BMD screening for women aged 65 and older, and for younger postmenopausal women whose 10-year fracture probability equals or exceeds that of a 65-year-old with no additional risk factors [7]. For a 52-year-old postmenopausal woman with a body weight below 70 kg and a parent with hip fracture, that threshold is typically met.

FRAX as the Bridge Between T-Score and Treatment

A T-score of -2.0 in a 52-year-old does not automatically mean medication. The FRAX tool (fracture risk assessment tool, developed by the WHO Collaborating Centre at Sheffield) integrates BMD with 11 clinical risk factors to estimate 10-year fracture probability [8]. The National Osteoporosis Foundation's treatment threshold is a 10-year hip fracture probability of 3% or a major osteoporotic fracture probability of 20% [3].

Interpreting DEXA in the 60s

By the early 60s, more than half of postmenopausal women have osteopenia and roughly 20% meet WHO criteria for osteoporosis, based on NHANES III data (N=14,646) [9]. Men reach their own accelerated loss phase around age 65-70 as free testosterone and growth hormone decline.

Reading the Scan Report in This Decade

Degenerative changes at L1-L4 become common enough that the lumbar spine T-score may read artificially high. A discordance of more than 1.0 SD between the spine and hip should prompt the clinician to rely on the hip score and potentially add a lateral vertebral assessment (LVA) to detect compression fractures [3].

Treatment Indications in the 60s

Bisphosphonate therapy is indicated for:

• T-score at or below -2.5 at any site, or
• T-score between -1.0 and -2.5 with a FRAX 10-year major fracture probability at or above 20%, or
• Any prior low-trauma vertebral or hip fracture regardless of T-score [3].

Alendronate 70 mg once weekly remains the first-line oral bisphosphonate, with three-year data from the Fracture Intervention Trial (FIT, N=2,027) showing a 47% reduction in hip fracture risk (RR 0.53, 95% CI 0.31-0.90) [10].

Interpreting DEXA in the 70s

Fracture risk accelerates sharply in this decade independent of T-score because bone quality (microarchitectural deterioration, cortical thinning) degrades at a rate that DEXA cannot capture. The Rotterdam Study (N=7,983) found that among adults over 70 with a hip fracture, approximately 30% did not have a T-score at or below -2.5 at the hip [11].

Trabecular Bone Score as an Adjunct

Trabecular Bone Score (TBS), a texture-based index derived from the DXA lumbar spine image, captures microarchitectural quality independently of BMD. A TBS below 1.200 is considered degraded microarchitecture. The International Society for Clinical Densitometry (ISCD) endorsed TBS as a valid FRAX adjustment tool in 2015 [12]. Not all DEXA software packages include TBS, so confirm availability before ordering.

Medication Choices in the 70s

Oral bisphosphonates remain effective, but adherence falls with polypharmacy. Zoledronic acid 5 mg IV once yearly is an option supported by the HORIZON-Key Fracture Trial (N=7,765), which showed a 41% relative reduction in vertebral fractures and a 25% reduction in non-vertebral fractures over three years [13]. For patients with T-score below -2.5 and very high fracture risk (prior hip or vertebral fracture), denosumab 60 mg subcutaneous every six months or teriparatide 20 mcg daily are second-line options.

Interpreting DEXA in the 80s and Beyond

After age 80, the Z-score is often more informative than the T-score because virtually all patients in this age group will have T-scores in the osteopenic or osteoporotic range. A Z-score above -1.0 in an 82-year-old indicates above-average bone density for peers, even if the T-score reads -2.8.

Fall Risk Outweighs BMD as a Fracture Predictor

A meta-analysis published in the BMJ (pooled N=37,983) found that the absolute number of falls predicts fracture more strongly than BMD after age 75 [14]. This does not mean DEXA is uninformative, but it means treatment decisions must incorporate fall-prevention programs, balance assessment, and medication review for fall-promoting drugs alongside the DEXA result.

Re-Scanning Intervals in Older Adults

The NOF recommends repeating DEXA every one to two years during active treatment to monitor response, and every two years once stable on therapy [3]. In patients over 80 who are not on pharmacological therapy, a five-year interval may be acceptable if baseline T-score is between -1.5 and -2.0.

Sex Differences in DEXA Interpretation

Men are under-screened. The USPSTF does not yet have a formal recommendation for male screening age, though the Endocrine Society and NOF recommend considering screening in men aged 70 and older, or in men aged 50-69 with risk factors including prior fracture, glucocorticoid use, or hypogonadism [3, 5].

Testosterone and Male BMD

Low testosterone in men causes accelerated cortical bone loss, predominantly at the hip. The Osteoporotic Fractures in Men (MrOS) study (N=5,995) showed that men with free testosterone in the lowest quartile had femoral neck BMD approximately 4% lower than men in the highest quartile [15]. TRT in hypogonadal men is associated with a 3-5% increase in lumbar spine BMD over 24 months in observational data, though no large randomized fracture-endpoint trial has been completed.

Hormone Therapy in Women

Menopausal hormone therapy (MHT) preserves BMD. The Women's Health Initiative (N=16,608) demonstrated that combined estrogen-progestin therapy reduced hip fracture incidence by 33% (HR 0.67, 95% CI 0.47-0.96) and vertebral fracture by 35% compared to placebo [16]. MHT is not FDA-approved as a primary osteoporosis treatment but is considered a reasonable option for women under 60 or within ten years of menopause who have concurrent vasomotor symptoms and low BMD.

Nutritional and Lifestyle Factors That Directly Alter DEXA Results

Pharmacology aside, four modifiable factors move the needle on serial DEXA scans:

Calcium and Vitamin D

The NOF recommends 1,000 mg elemental calcium per day for men aged 50-70 and 1,200 mg per day for women over 50 and men over 70, with a vitamin D intake of 800-1,000 IU per day [3]. Serum 25-OH-D levels below 20 ng/mL are associated with secondary hyperparathyroidism, accelerating bone resorption.

Resistance Exercise

A 2022 meta-analysis in the Journal of Bone and Mineral Research (45 RCTs, N=4,015) found progressive resistance training produced a mean BMD gain of 1.03% at the lumbar spine (95% CI 0.53-1.52%) and 0.56% at the femoral neck compared to control over 12 months [17].

Protein Intake

Dietary protein at or above 1.2 g/kg/day is associated with higher BMD in observational data from the Framingham Osteoporosis Study (N=615) [18]. Very low protein intake accelerates muscle loss, which reduces mechanical loading on bone.

Smoking and Alcohol

Smokers have BMD approximately 5-10% lower than non-smokers at the hip, and heavy alcohol use (more than 3 units per day) is an independent risk factor in the FRAX calculator. Cessation of smoking is associated with partial BMD recovery over 5-10 years.

When DEXA Alone Is Not Enough: Advanced Imaging

The following decision framework summarizes when to go beyond standard DEXA:

Order TBS when the lumbar spine T-score and FRAX risk feel discordant, particularly in type 2 diabetes (where FRAX underestimates fracture risk because BMD is often normal despite poor bone quality) or in patients on long-term glucocorticoids.

Order Lateral Vertebral Assessment (LVA) when lumbar spine T-score is below -1.5, the patient has lost more than 4 cm of height, or there is kyphosis on exam. LVA can identify morphometric vertebral fractures at very low radiation dose and upgrades the clinical classification to severe osteoporosis if found.

Order QCT (quantitative CT) in patients where DEXA is unreliable: severe obesity (BMI above 40), significant scoliosis, or bilateral hip prostheses.

Order bone turnover markers (serum CTX for resorption, serum P1NP for formation) to monitor treatment response between DEXA scans. CTX decreasing by more than 25% from baseline after 3 months on a bisphosphonate confirms adherence and biologic response.

Alendronate and Bisphosphonate Drug Holidays

Bisphosphonates accumulate in bone and continue to provide some protection after discontinuation, a property that makes drug holidays clinically feasible. Current ASBMR guidance (2016 task force report) recommends:

• After 5 years of oral bisphosphonate (or 3 years of IV zoledronic acid), reassess fracture risk.
• If hip T-score is above -2.5 and no incident fractures have occurred, a drug holiday of 2-3 years is reasonable.
• Patients with T-score at or below -2.5 at the hip, or with prior hip or vertebral fracture, should generally continue therapy or transition to an alternative agent rather than stopping [19].

Atypical femoral fractures (AFFs), the most widely publicized long-term bisphosphonate risk, occur at a rate of approximately 3.2-50 per 100,000 person-years depending on treatment duration, compared to a hip fracture incidence exceeding 1,000 per 100,000 person-years in women over 80 [20].

Serial DEXA Monitoring: What Change Is Real?

DEXA has a precision error, typically 1-1.5% at the spine and 1.5-2% at the hip in experienced centers. The Least Significant Change (LSC) is the minimum change that exceeds measurement error at 95% confidence. For most DEXA centers, the LSC is approximately 2.8-4% at the spine and 3.5-5% at the hip [12].

A gain of 1.5% at the lumbar spine after two years of alendronate is within measurement noise. A gain of 5% at the spine represents a real improvement. Clinicians quoting fractional percentage changes without referencing the LSC of their specific machine are misreading precision data.

The ISCD recommends that patients be scanned on the same machine by the same technologist whenever possible to minimize inter-scan variability [12].